contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  createdAt
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
    forum {
      threadUrl
    }
    defaultInstrument {
      symbol
      id
    }
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        threadUrl
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        symbol
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
      researchContent {
        title
        lang
        pdfUrl
        relatedContent {
          __typename
          ...PublishingDetails
          ...Reactions
          id
        }
        content {
          title
          lang
          htmlBody
          publishedAt
          createdAt
          changedAt
          isOutdated
          isPremium
        }
      }
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


azt-arcticzymes-technologies-asa-to-present-at-the-pareto-securities-17th-annual-healthcare-conference-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

ArcticZymes Technologies is active in biotechnology. The company specializes in research and development of drugs for the treatment of autoimmune diseases. The main focus is on the development of glucans, the production of immunostimulants, and the analysis of enzymes. The vision is to test and develop the medicine and then further use it for RNA and DNA processes. The company was previously known as Biotec Pharmacon and is headquartered in Tromsø.

MFN – 27 Jan 22              ArcticZymes Technologies: AZT: ArcticZymes Technologies Q4 2021 Res...    Tromsø, Norway, 27[th] January 2022 - ArcticZymes Technologies (OSE: AZT) reported sales of NOK 40.5 million (22.1) and an EBITDA of NOK 20.8 million (6.8) for the fourth quarter of 2021. Highligh...

Højdepunkter fra 2. kvartal 2021 · ArcticZymes Technologies (AZT) havde en omsætning på 21,4 mio. NOK i 2. kvartal – en reduktion på 36 % (2. kvartal 2020: 33,4 mio. NOK)  · Coronavirus-relateret salg estimeres til 4,5 mio. NOK i 2. kvartal 2021 (11,0 mio. NOK i 2. kvartal 2020)  · Bruttofortjenesten reduceredes til 21,6 mio. NOK som følge af lavere salg (2. kvartal 2020: 33,0 mio. NOK)  · AZT genererede en positiv EBITDA på 6,0 mio. NOK (2. kvartal 2020: 22,5 mio. NOK)  · Pengestrømmen for 2. kvartal var positiv 13,6 mio. NOK (2. kvartal 2020: 20,4 mio. NOK), hvilket gav en likvid beholdning på 177,0 mio. NOK (2. kvartal 2020: 56,1 mio. NOK)  · Lancerede SAN HQ 2.0 i slutningen af kvartalet  · Øget ejerskab i ArcticZymes AS fra 96 % til 100 % ved kapitalindskud in natura

Jeg har fulgt med, måske lidt for meget.  100x San-HQ produktionskapacitet ved udgangen af sidste kvartal. San 2.0 udgivet, salg starter i slutningen af Q3, hvilket muliggør en bredere kundebase. Lab-a-porter ny distributør Ny MDx kunde Virus X rapport færdig – bag betalingsmur Arctic-produkter begynder at dukke op på kinesiske hjemmesider Test af Covid-tests er ikke faldet Sidste kvartal nævnte 2 store cGMP-auditører Institutionel ejerskab er steget. Reitheras finansieringsproblemer vanskeliggør og forsinker vaccinegodkendelse. Heldigvis har dem, der har fået to vacciner, fået en greenpass med en undtagelse. Spekulationer om, at Mexico ville være med i næste fase. Der har været spekulationer om en anden coronavaccineproducent, men navnet er ikke offentliggjort (Sanofi har optrådt på norske fora, spekulationer). Mål om at tilføje porteføljen inden for 2-3 år. Personlig mistanke er, at virksomheden også vil begynde at interessere potentielle købere. Globalt enzymmarked forventes at vokse med 9,4 % i 2027 (CAGR), tidligere prognose var 7 %. Pareto sænkede sin anbefaling fra 135 nok til 133 nok. Har coronasituationen vanskeliggjort salg eller nye kontrakter? Cykliske ordrer?  Kilder:                  arcticzymes.com              ArcticZymes Technologies | The Enzyme Experts    Leading enzymes for biomanufacturing and diagnostics, brought to you by the inventors of COD UNG and salt-active nucleases.                            https://lab-a-porter.com/2021/06/novel-enzymes-from-the-arctic/           Our World in Data              Total COVID-19 tests    Comparisons across countries are affected by differences in testing policies and reporting methods.                             Generelt set har folk ret moderate forventninger, og corona-indtægter bliver konsekvent nedtonet/minimeret. Kunder og lignende virksomheder har leveret gode kvartalsresultater.  I tilfældet med denne virksomhed skal du stole på din egen forskning og ikke lytte til, hvad andre siger.

Fra Marketscreener er der et skøn på 30 MNOK i omsætning og 14 MNOK i EBIT. Dette er baseret på en enkelt analytikers prognose, hvilket må betyde Pareto, som er det eneste analysehus, der har angivet et kursmål.

Q2-rapporten kommer næste torsdag. Er der nogen (@SuperB), der har fulgt nyhederne for nylig, hvad forventes der?

hegnarmedia.auth.zephr.com – 3 May 21              Meglerhus tror kursfesten fortsetter    Pareto Securities forventer videre kursoppgang i ArcticZymes Technologies.                             Paretos kursmål for AZT-aktien er 135 i morges

Reithera – 26 Apr 21              ReiThera Completes Enrolment of Subjects in the Phase 2 Part of the Phase 2/3...    ROME, Italy, April 26th, 2021 – ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies, announces that it has completed the...         Est. reading time: 3 minutes                               Arcticzymes leverer SAN-saltnuklease (SAN nuclease) til Reithera til vaccinen.

ArcticZymes Technologies

(Tromsø, 02 September 2026) ArcticZymes Technologies ASA (OSE:AZT) will present at Pareto Securities 17th Healthcare Conference in Stockholm taking place today, 02 September 2026. Estimated ...

<pre>(Tromsø, 02 September 2026) ArcticZymes Technologies ASA (OSE:AZT) will present at Pareto Securities 17th Healthcare Conference in Stockholm taking place today, 02 September 2026. Estimated start of the presentation will be at 13.10 CET. Speaker will be CEO, Michael Akoh Please find the presentation enclosed For further information: Børge Sørvoll CFO +47 950 90 187 ir@arcticzymes.com ir@arcticzymes.com\ </pre>

Privatlivspræferencer

AZT: ArcticZymes Technologies ASA to present at the Pareto Securities' 17th Annual Healthcare Conference 2026

AZT: ArcticZymes Technologies ASA to present at the Pareto Securities' 17th Annual Healthcare Conference 2026